Evidence-Based Medical News

Mode

All Infectious Disease Oncology Neurology Cardiology Psychiatry Diabetes & Endocrinology Pediatrics Allergy & Immunology Rheumatology Gastroenterology Primary Care & Family Medicine Nutrition & Obesity Medicine OB/GYN & Women's Health Orthopedics & Sports Medicine Genetics & Precision Medicine Radiology & Imaging Pulmonology & Critical Care Anesthesiology & Pain Medicine Physical Medicine & Rehab Nephrology Hematology Dermatology Urology Emergency Medicine Ophthalmology Geriatrics & Aging ENT (Otolaryngology) Palliative Care

Research

Clinical Trials Drug Pipeline Weekly Digests

Reference

Conditions Medications

Community

Text Size

Log in / Sign up

temozolomide

4 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of temozolomide

143 trials tracked of temozolomide: 13 in phase 3 or 4 and 6 with published results. The most-cited published study has 2784 citations.

143Trials tracked

13Phase 3 & 4

0Recruiting

6With published results

Phase distribution

Phase 4 2 Phase 3 11 Phase 2 112 Phase 1 13 Other / NA 5

Phase 3 Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma Completed · 2,784 cited
Phase 3 Radiation Therapy With or Without Temozolomide in Treating Older Patients With Newly Diagnosed Glioblastoma Multiforme Completed · 1,171 cited
Phase 3 An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) Completed · 490 cited
Phase 3 An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) Completed · 474 cited
Phase 3 A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification Completed · 111 cited
Phase 3 Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma Completed · 20 cited

Show 44 more trials

Phase 4 Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572) Completed
Phase 4 Bioequivalence Study of Temozolomide in Patients With Primary Tumors of the Central Nervous System Completed
Phase 3 Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma Completed
Phase 3 A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma Completed
Phase 3 Temozolomide Versus Dacarbazine in Stage IV Metastatic Melanoma (Study P03267) Completed
Phase 3 A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma Completed
Phase 3 Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status Completed
Phase 2 Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma Completed
Phase 2 Study of Bevacizumab Plus Temodar and Tarceva in Patients With Glioblastoma or Gliosarcoma Completed
Phase 2 Presurgery Bortezomib for Recurrent Malignant Gliomas Followed by Postop Bortezomib & Temozolomide Completed
Phase 2 Temozolomide 12 Cycles Versus 6 Cycles of Standard First-line Treatment in Patients With Glioblastoma. Completed
Phase 2 Radiation Therapy, Temozolomide, and Lomustine in Treating Young Patients With Newly Diagnosed Gliomas Completed
Phase 2 A Study of Bevacizumab and Extended Treatment of Temozolomide in Patients With Recurrent Glioblastoma Multiforme Completed
Phase 2 Temozolomide Chronotherapy for High Grade Glioma Completed
Phase 2 Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma Completed
Phase 2 Hypofractionated Intensity-Modulated Radiation Therapy With Temozolomide and Bevacizumab for Glioblastoma Multiforme Completed
Phase 2 A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed Glioblastoma Completed
Phase 2 Phase II Study of Gamma Knife Radiosurgery and Temozolomide for Brain Metastases Completed
Phase 2 Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors Completed
Phase 2 Temozolomide in Treating Patients With Low-Grade Glioma Completed
Phase 2 Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma Completed
Phase 2 ABT-888 and Temozolomide for Metastatic Breast Cancer and BRCA1/2 Breast Cancer Completed
Phase 2 A Study of Avastin (Bevacizumab) and Irinotecan Versus Temozolomide Radiochemistry in Patients With Glioblastoma Completed
Phase 2 Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Completed
Phase 2 Phase 1-2 of Temozolomide and Hypofractionated Radiotherapy in Tx of Supratentorial Glioblastoma Multiform Completed
Phase 2 Avastin in Combination With Radiation (XRT) & Temozolomide, Followed by Avastin, Temozolomide and Irinotecan for Glioblastoma (GBM) and Gliosarcomas Completed
Phase 2 Dose-Intense Temozolomide in Recurrent Glioblastoma Completed
Phase 2 Phase 1/2 Study of Enzastaurin in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients Completed
Phase 2 Temozolomide and Sorafenib in Treating Patients With Metastatic or Unresectable Melanoma Completed
Phase 2 Radiation Therapy and Temozolomide Followed by Temozolomide Plus Sorafenib for Glioblastoma Multiforme Completed
Phase 2 Bevacizumab Beyond Progression (BBP) Completed
Phase 2 Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Unmethylated Gene Promoter Status Completed
Phase 2 PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation Completed
Phase 2 Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Completed
Phase 2 Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma Completed
Phase 2 Carboplatin and Temozolomide (Temodar) for Recurrent and Symptomatic Residual Brain Metastases Completed
Phase 2 Thalidomide and Temozolomide in Relapsed or Progressive CNS Disease or Neuroblastoma Completed
Phase 2 Study of MLN8237 in Combination With Irinotecan and Temozolomide Completed
Phase 2 Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma Completed
Phase 2 M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers Completed
Phase 2 Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide (TMZ) or In Combination With Carboplatin and Paclitaxel Versus Placebo in Participants With Breast Cancer Gene (BRCA)1 and BRCA2 Mutation and Metastatic Breast Cancer Completed
Phase 2 Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery Completed
Phase 2 Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors Completed
Phase 2 A Study of ABT-888 in Combination With Temozolomide for Colorectal Cancer Completed

Showing the 50 most-cited and recently-updated of 143 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.